|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Personalized medicine in functional gastrointestinal disorders:Understanding pathogenesis to increase diagnostic and treatment efficacy显示文摘There is overwhelming evidence that functional gastrointestinal disorders(FGIDs) are associated with specific mechanisms that constitute important targets for personalized treatment. There are specific mechanisms in patients presenting with functional upper gastrointestinal symptoms(UGI Sx). Among patients with UGI Sx, approximately equal proportions(25%) of patients have delayed gastric emptying(GE), reduced gastric accommodation(GA), both impaired GE and GA,or neither, presumably due to increased gastric or duodenal sensitivity.Treatments targeted to the underlying pathophysiology utilize prokinetics,gastric relaxants, or central neuromodulators. Similarly, specific mechanisms in patients presenting with functional lower gastrointestinal symptoms, especially with diarrhea or constipation, are recognized, including at least 30% of patients with functional constipation pelvic floor dyssynergia and 5% has colonic inertia(with neural or interstitial cells of Cajal loss in myenteric plexus); 25% of patients with diarrhea-predominant irritable bowel syndrome(IBSD) has evidence of bile acid diarrhea; and, depending on ethnicity, a varying proportion of patients has disaccharidase deficiency, and less often sucrose-isomaltase deficiency. Among patients with predominant pain or bloating, the role of fermentable oligosaccharides, disaccharides, monosaccharides and polyols should be considered. Personalization is applied through pharmacogenomics related to drug pharmacokinetics, specifically the role of CYP2 D6, 2 C19 and 3 A4 in the use of drugs for treatment of patients with FGIDs. Single mutations or multiple genetic variants are relatively rare, with limited impact to date on the understanding or treatment of FGIDs. The role of mucosal gene expression in FGIDs, particularly in IBS-D, is the subject of ongoing research. In summary, the time for personalization of FGIDs, based on deep phenotyping, is here;pharmacogenomics is relevant in the use of central neuromodulators. There is still unclear impact of the role of genetics in the management of FGIDs. | Xiao Jing Wang Michael Camilleri | 2019 | World Journal of Gastroenterology2019，25，10： | 7 |
| 2 | Functional Gastroduodenal Disorders显示文摘 | Jan Tack Nicholas J. Talley Michael Camilleri Gerald Holtmann Pinjin Hu Juan-R. Malagelada Vincenzo Stanghellini | 2006 | Gastroenterology2006，，5： | 3 |
| 3 | Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome显示文摘 | Banny S. Wong Michael Camilleri Irene Busciglio Paula Carlson Lawrence A. Szarka Duane Burton Alan R. Zinsmeister | 2011 | Gastroenterology2011，，5： | 3 |
| 4 | Re: Halmos et al, A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome显示文摘 | Michael Camilleri Andres Acosta | 2014 | Gastroenterology2014，，7： | 3 |
| 5 | Brain-Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders显示文摘 | Michael Camilleri Carlo Di Lorenzo | 2012 | Journal of Pediatric Gastroenterology and Nutrition2012，，4： | 2 |
| 6 | Review: Management of Postprandial Diarrhea Syndrome显示文摘 | Mary E. Money Michael Camilleri | 2012 | The American Journal of Medicine2012，，6： | 2 |
| 7 | Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases显示文摘 | Madhusudan Grover Michael Camilleri | 2013 | Journal of Gastroenterology2013，，2： | 2 |
| 8 | Effects of matrix moisture on gas diffusion and flow in coal显示文摘 | Zhejun Pan Luke D. Connell Michael Camilleri Leo Connelly | 2010 | Fuel2010，，11： | 2 |
| 9 | Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus显示文摘The worldwide rise in the prevalence of obesity supports the need for an increased interaction between ongoing clinical research in the allied fields of gastrointestinal medicine/surgery and diabetes mellitus. There have been a number of clinically-relevant advances in diabetes, obesity, and metabolic syndrome emanating from gastroenterological research. Gastric emptying is a significant factor in the development of upper gastrointestinal symptoms. However, it is not the only mechanism whereby such symptoms occur in patients with diabetes. Disorders of intrinsic pacing are involved in the control of stomach motility in patients with gastroparesis; on the other hand, there is limited impact of glycemic control on gastric emptying in patients with established diabetic gastroparesis. Upper gastrointestinal functions related to emptying and satiations are significantly associated with weight gain in obesity. Medications used in the treatment of diabetes or metabolic syndrome, particularly those related to pancreatic hormones and incretins affect upper gastrointestinal tract function and reduce hyperglycemia and facilitate weight loss. The degree of gastric emptying delay is significantly correlated with the weight loss in response to liraglutide, a glucagonlike peptide-1 analog. Network meta-analysis shows that liraglutide is one of the two most efficacious medical treatments of obesity, the other being the combination treatment phentermine-topiramate. Interventional therapies for the joint management of obesity and diabetes mellitus include newer endoscopic procedures, which require long-term follow-up and bariatric surgical procedure for which long-term follow up shows advantages for individuals with diabetes. Newer bariatric procedures are presently undergoing clinical evaluation. On the horizon, combination therapies, in part directed at gastrointestinal functions, appear promising for these indications. Ongoing and future gastroenterological research when translated to care of individuals with diabetes mellitus should provide additional options to improve their clinical outcomes. | Timothy R Koch Timothy R Shope Michael Camilleri | 2018 | World Journal of Diabetes2018，9，11： | 2 |
| 10 | A Controlled Trial of Gluten-Free Diet in Patients With Irritable Bowel Syndrome-Diarrhea: Effects on Bowel Frequency and Intestinal Function显示文摘 | Maria I. Vazquez–Roque Michael Camilleri Thomas Smyrk Joseph A. Murray Eric Marietta Jessica O’Neill Paula Carlson Jesse Lamsam Denise Janzow Deborah Eckert Duane Burton Alan R. Zinsmeister | 2013 | Gastroenterology2013，，5： | 2 |
| 11 | Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms显示文摘 | Michael Camilleri | 2014 | J Physiol2014，，14： | 2 |
| 12 | Diabetic Gastroparesis显示文摘 | Michael Camilleri | 2007 | The New England Jour- nal of Medicine2007，356，8： | 1 |
| 13 | Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist显示文摘 | Michael Camilleri | 2004 | Clinical Gastroenterology and Hepatology2004，，3： | 1 |
| 14 | Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation显示文摘 | Sunanda V Kane William J Sandborn Paul A Rufo Anna Zholudev James Boone David Lyerly Michael Camilleri Stephen B Hanauer | 2003 | The American Journal of Gastroenterology2003，，： | 1 |
| 15 | Impacts of cli- mate change on building performance in New Zealand 显示文摘 | Michael Camilleri Roman Jaques Nigel Lsaacs | 2001 | Build Research & Information2001，29，6： | 1 |
| 16 | The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients With Type 1 Diabetes Mellitus显示文摘 | Andrea Shin Michael Camilleri Irene Busciglio Duane Burton Steven A. Smith Adrian Vella Michael Ryks Deborah Rhoten Alan R. Zinsmeister | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 17 | Pharmacodynamic and Clinical Endpoints for Functional Colonic Disorders: Statistical Considerations显示文摘 | Alan R. Zinsmeister Duane Burton Michael Camilleri | 2013 | Digestive Diseases and Sciences2013，，2： | 1 |
| 18 | 925g Plecanatide, a Novel Guanylate Cyclase-C (GC-C) Receptor Agonist, is Efficacious and Safe in Patients with Chronic Idiopathic Constipation (CIC): Results from a 951 Patient, 12 Week, Multi-Center Trial显示文摘 | Philip B. Miner Ron Surowitz Ron Fogel William Koltun Douglas A. Drossman Michael Camilleri Allen Mangel Laura Barrow Gary S. Jacob Kunwar Shailubhai | 2013 | Gastroenterology2013，，5： | 1 |
| 19 | Gastrointestinal problems in diabetes 显示文摘 | Michael Camilleri | 1996 | Endocrinal Metab Clin North Am1996，25，3： | 1 |
| 20 | A ran- domised controlled study of the effect of cholinesterase inhibitor on colon function in patients with diabetes mellitus and constipa- tion显示文摘 | Adil E Bharucha Phillip Low Michael Camilleri | 2013 | Gut2013，62，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员